ACRBP

Summary

ACRBP (acrosin binding protein, HGNC:17195) is a protein-coding gene on chromosome 12p13.31, encoding Acrosin-binding protein (Q8NEB7). Acrosomal protein that maintains proacrosin (pro-ACR) as an enzymatically inactive zymogen in the acrosome.

The protein encoded by this gene is similar to proacrosin binding protein sp32 precursor found in mouse, guinea pig, and pig. This protein is located in the sperm acrosome and is thought to function as a binding protein to proacrosin for packaging and condensation of the acrosin zymogen in the acrosomal matrix. This protein is a member of the cancer/testis family of antigens and it is found to be immunogenic. In normal tissues, this mRNA is expressed only in testis, whereas it is detected in a range of different tumor types such as bladder, breast, lung, liver, and colon.

Source: NCBI Gene 84519 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 93 total — 4 pathogenic
• MANE Select transcript: NM_032489

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17195
Approved symbol	ACRBP
Name	acrosin binding protein
Location	12p13.31
Locus type	gene with protein product
Status	Approved
Aliases	SP32, OY-TES-1, CT23
Ensembl gene	ENSG00000111644
Ensembl biotype	protein_coding
OMIM	608352
Entrez	84519

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 4 protein_coding, 2 retained_intron, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000229243, ENST00000414226, ENST00000535884, ENST00000536350, ENST00000538524, ENST00000540513, ENST00000542357, ENST00000544352, ENST00000546114

RefSeq mRNA: 1 — MANE Select: NM_032489 NM_032489

CCDS: CCDS8554

Canonical transcript exons

ENST00000229243 — 10 exons

Exon	Start	End
ENSE00000715443	6643539	6643671
ENSE00000715594	6646794	6647012
ENSE00000866934	6644137	6644605
ENSE00002314500	6647324	6647432
ENSE00003527491	6640060	6640227
ENSE00003527697	6646483	6646577
ENSE00003574337	6645220	6645337
ENSE00003574491	6638075	6638404
ENSE00003647799	6638954	6639037
ENSE00003663449	6640343	6640522

Expression profiles

Bgee: expression breadth ubiquitous, 177 present calls, max score 99.16.

FANTOM5 (CAGE): breadth broad, TPM avg 6.1225 / max 1145.3048, expressed in 725 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
129152	2.8152	608
129144	1.8849	118
129145	1.1389	116
129153	0.1846	35
129151	0.0761	14
206554	0.0121	4
129150	0.0108	3

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	99.16	gold quality
right testis	UBERON:0004534	98.89	gold quality
monocyte	CL:0000576	98.42	gold quality
leukocyte	CL:0000738	98.11	gold quality
sperm	CL:0000019	97.40	gold quality
adult organism	UBERON:0007023	97.23	gold quality
testis	UBERON:0000473	96.85	gold quality
granulocyte	CL:0000094	95.03	gold quality
blood	UBERON:0000178	92.32	gold quality
spleen	UBERON:0002106	89.96	gold quality
right lung	UBERON:0002167	88.14	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.16	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.13	gold quality
corpus epididymis	UBERON:0004359	85.25	gold quality
bone marrow cell	CL:0002092	82.61	gold quality
bone marrow	UBERON:0002371	80.17	gold quality
right uterine tube	UBERON:0001302	79.91	gold quality
left lobe of thyroid gland	UBERON:0001120	79.80	gold quality
right lobe of thyroid gland	UBERON:0001119	79.69	gold quality
upper lobe of left lung	UBERON:0008952	79.56	gold quality
thyroid gland	UBERON:0002046	79.53	gold quality
trabecular bone tissue	UBERON:0002483	77.99	gold quality
right hemisphere of cerebellum	UBERON:0014890	77.97	gold quality
cerebellar hemisphere	UBERON:0002245	77.58	gold quality
upper lobe of lung	UBERON:0008948	77.49	gold quality
cerebellar cortex	UBERON:0002129	77.38	gold quality
cerebellum	UBERON:0002037	76.21	gold quality
gall bladder	UBERON:0002110	75.52	gold quality
islet of Langerhans	UBERON:0000006	75.49	gold quality
vermiform appendix	UBERON:0001154	75.35	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-MTAB-10432	yes	5545.83
E-MTAB-9221	yes	4762.73
E-MTAB-7407	yes	3936.47
E-GEOD-150728	yes	3200.67
E-HCAD-4	yes	33.00
E-GEOD-134144	yes	29.34
E-HCAD-1	yes	9.22
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

21 targeting ACRBP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-128-1-5P	99.33	60.46	332
HSA-MIR-128-2-5P	99.33	60.83	311
HSA-MIR-3925-5P	99.21	67.90	1466
HSA-MIR-6814-5P	99.03	66.68	1273
HSA-MIR-330-5P	98.73	67.63	1788
HSA-MIR-326	98.25	66.44	1565
HSA-MIR-4736	97.96	65.89	1287
HSA-MIR-3620-5P	97.42	63.95	792
HSA-MIR-1587	96.95	64.03	932
HSA-MIR-4296	96.35	63.55	1233
HSA-MIR-6747-5P	96.17	64.99	743

Literature-anchored findings (GeneRIF, showing 9)

• We showed identification of HLA-A24-binding OY-TES-1 peptide, TES(401-409) (KTPFVSPLL) recognized by CD8 T-cells. (PMID:16301813)
• High ACRBP expression correlated with reduced survival time and faster relapse among ovarian cancer patients. (PMID:20876808)
• The down-regulation of OY-TES-1 expression in bone marrow-derived mesenchymal stem cells caused cell growth inhibition, cell cycle arrest, apoptosis induction and migration ability attenuation. (PMID:22651134)
• OY-TES-1 is frequently expressed in colorectal carcinoma and is able to induce humoral immune response spontaneously in CRC patients. (PMID:24294369)
• OY-TES-1 downregulation in liver cancer cells caused 2 opposite effects on cell proliferation: promotion by upregulating CCND2 and CDCA3, and inhibition by CD9 upregulation and NANOG downregulation. OY-TES-1 may play multiple roles in liver cancer. (PMID:25673160)
• OY-TES-1 was expressed in ovarian cancer (OC) tissues with a high proportion, and some of OC tissues presented OY-TES-1 expression in high level vs OC adjacent tissues. (PMID:26189257)
• Down regulation of OY-TES-1 increased expression of apoptosis-regulated protein caspase-3, and decreased expression of cell cycle-regulated protein cyclin E, migration/invasion-regulated proteins MMP2 and MMP9. (PMID:26339343)
• Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma. (PMID:32862383)
• CT23 knockdown attenuating malignant behaviors of hepatocellular carcinoma cell is associated with upregulation of metallothionein 1. (PMID:33559934)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Acrbp	ENSMUSG00000072770
rattus_norvegicus	Acrbp	ENSRNOG00000017399

Protein

Protein identifiers

Acrosin-binding protein — Q8NEB7 (reviewed: Q8NEB7)

Alternative names: Acrosin-binding protein, 60 kDa form, Cancer/testis antigen 23, Cancer/testis antigen OY-TES-1, Proacrosin-binding protein sp32

All UniProt accessions (6): Q8NEB7, A0A140VJD6, E7EP66, F5H2C2, F5H3P4, F5H5S8

UniProt curated annotations — full annotation on UniProt →

Function. Acrosomal protein that maintains proacrosin (pro-ACR) as an enzymatically inactive zymogen in the acrosome. Involved also in the acrosome formation.

Subunit / interactions. Binds proacrosin (pro-ACR). Does not bind the mature form of ACR.

Subcellular location. Secreted. Cytoplasmic vesicle. Secretory vesicle. Acrosome.

Tissue specificity. Expression restricted to testis in normal tissue. Expressed in a wide spectrum of cancers, including bladder, breast, liver, lung and colon cancers.

Post-translational modifications. Phosphorylated on Tyr residues in capacitated sperm. The N-terminus is blocked. Synthesized as a 60-kDa precursor, the 32-kDa mature form is post-translationally produced by the removal of the N-terminal half of the precursor during sperm maturation in the testis and/or epididymis.

RefSeq proteins (1): NP_115878* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009865	Proacrosin-bd	Family
IPR036058	Kazal_dom_sf	Homologous_superfamily

Pfam: PF07222

UniProt features (13 total): region of interest 3, compositionally biased region 3, chain 2, sequence conflict 2, signal peptide 1, sequence variant 1, propeptide 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NEB7-F1	64.09	0.25

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 94 (showing top): WHITEHURST_PACLITAXEL_SENSITIVITY, GOCC_SECRETORY_GRANULE, GOBP_VESICLE_ORGANIZATION, KORKOLA_CHORIOCARCINOMA_DN, GOBP_MALE_GAMETE_GENERATION, GOBP_SECRETORY_GRANULE_ORGANIZATION, GOBP_CELLULAR_COMPONENT_ASSEMBLY_INVOLVED_IN_MORPHOGENESIS, KORKOLA_EMBRYONAL_CARCINOMA_DN, GOBP_ACROSOME_ASSEMBLY, GOBP_ORGANELLE_ASSEMBLY, GOBP_CELLULAR_PROCESS_INVOLVED_IN_REPRODUCTION_IN_MULTICELLULAR_ORGANISM, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, CCCAGAG_MIR326, GOBP_FERTILIZATION

GO Biological Process (3): acrosome assembly (GO:0001675), spermatid development (GO:0007286), fertilization (GO:0009566)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): acrosomal vesicle (GO:0001669), acrosomal membrane (GO:0002080), extracellular region (GO:0005576), nucleus (GO:0005634), cytoplasmic vesicle (GO:0031410)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
developmental process involved in reproduction	1
spermatid development	1
cellular component assembly involved in morphogenesis	1
cellular process involved in reproduction in multicellular organism	1
secretory granule organization	1
organelle assembly	1
germ cell development	1
spermatid differentiation	1
sexual reproduction	1
reproductive process	1
binding	1
secretory granule	1
acrosomal vesicle	1
secretory granule membrane	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1
cytoplasm	1
intracellular vesicle	1

Protein interactions and networks

STRING

1004 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ACRBP	LIPI	Q6XZB0	690
ACRBP	ZPBP2	Q6X784	686
ACRBP	ACR	P10323	654
ACRBP	ZPBP	Q9BS86	649
ACRBP	SPA17	Q15506	646
ACRBP	ADAM2	P78326	618
ACRBP	CAGE1	Q8TC20	606
ACRBP	SAGE1	Q9NXZ1	595
ACRBP	PRSS50	Q9UI38	580
ACRBP	SPACA3	Q8IXA5	561
ACRBP	MAGEC1	O60732	540
ACRBP	SPACA1	Q9HBV2	537
ACRBP	SPAM1	P38567	522
ACRBP	AKAP3	O75969	518
ACRBP	ODF1	Q14990	500

IntAct

4 interactions, top by confidence:

A	B	Type	Score
ACRBP	MYO9A	psi-mi:“MI:0914”(association)	0.350
MAN2B1	IGF2R	psi-mi:“MI:0914”(association)	0.350
ACRBP	SBNO1	psi-mi:“MI:0914”(association)	0.350

BioGRID (21): ACRBP (Affinity Capture-MS), ACRBP (Positive Genetic), MYO5C (Affinity Capture-MS), ARFGAP2 (Affinity Capture-MS), MBD3 (Affinity Capture-MS), CEP164 (Affinity Capture-MS), MYO9A (Affinity Capture-MS), TOR3A (Affinity Capture-MS), DEPDC1B (Affinity Capture-MS), ACRBP (Affinity Capture-MS), ACRBP (Affinity Capture-MS), PTOV1 (Affinity Capture-MS), MTA3 (Affinity Capture-MS), IQGAP3 (Affinity Capture-MS), RIPK4 (Affinity Capture-MS)

ESM2 similar proteins: A2A699, A2ALI5, A2AWH2, A2BD09, A2BDP1, A4IFM1, A4IHZ3, A6QLD2, A6QPA0, A8MVW0, B0BN44, B1AL88, F1N4E5, O14525, O15105, O35144, O35253, O75129, O75949, O88406, O94983, P0C7U0, P0CG37, P51693, Q03157, Q29016, Q2F7Z7, Q3T0Q2, Q3UPI1, Q4W8E7, Q5EGE1, Q5PQX1, Q61137, Q68BL7, Q68BL8, Q6H9L7, Q6UWH4, Q766D5, Q76KP1, Q80Z10

Diamond homologs: Q29016, Q3V140, Q60485, Q6AY33, Q8NEB7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

93 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	4
Likely pathogenic	0
Uncertain significance	72
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
146024	GRCh38/hg38 12p13.33-13.31(chr12:45740-6945196)x3	Pathogenic
563988	GRCh37/hg19 12p13.33-13.31(chr12:191242-8122785)x3	Pathogenic
625811	GRCh37/hg19 12p13.33-13.31(chr12:189216-8185497)	Pathogenic
685635	GRCh37/hg19 12p13.33-13.31(chr12:173786-8393815)x3	Pathogenic

SpliceAI

1485 predictions. Top by Δscore:

Variant	Effect	Δscore
12:6639033:CAAAT:C	acceptor_gain	1.0000
12:6639051:C:CT	acceptor_gain	1.0000
12:6640338:GATAC:G	donor_loss	1.0000
12:6640339:ATAC:A	donor_loss	1.0000
12:6640340:TA:T	donor_loss	1.0000
12:6640341:A:C	donor_loss	1.0000
12:6640342:C:CG	donor_loss	1.0000
12:6640518:CAGAC:C	acceptor_gain	1.0000
12:6640524:T:G	acceptor_loss	1.0000
12:6643537:A:AC	donor_gain	1.0000
12:6643538:C:CC	donor_gain	1.0000
12:6643538:CCGA:C	donor_gain	1.0000
12:6643541:A:AC	donor_gain	1.0000
12:6643542:C:CC	donor_gain	1.0000
12:6643544:T:TA	donor_gain	1.0000
12:6643545:C:A	donor_gain	1.0000
12:6643564:T:TA	donor_gain	1.0000
12:6643577:T:TA	donor_gain	1.0000
12:6644129:T:TA	donor_gain	1.0000
12:6644362:T:TA	donor_gain	1.0000
12:6644367:AGT:A	donor_gain	1.0000
12:6644367:AGTC:A	donor_gain	1.0000
12:6644367:AGTCC:A	donor_gain	1.0000
12:6644371:C:A	donor_gain	1.0000
12:6644376:T:TA	donor_gain	1.0000
12:6644380:T:TA	donor_gain	1.0000
12:6644383:T:A	donor_gain	1.0000
12:6644384:C:A	donor_gain	1.0000
12:6644392:C:A	donor_gain	1.0000
12:6644395:T:TA	donor_gain	1.0000

AlphaMissense

3544 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:6640108:C:A	W459C	0.999
12:6640108:C:G	W459C	0.999
12:6646523:A:C	F106C	0.999
12:6646532:A:C	F103C	0.999
12:6646540:A:C	F100L	0.999
12:6646540:A:T	F100L	0.999
12:6646541:A:C	F100C	0.999
12:6646542:A:G	F100L	0.999
12:6646813:G:C	N81K	0.999
12:6646813:G:T	N81K	0.999
12:6646894:C:A	W54C	0.999
12:6646894:C:G	W54C	0.999
12:6638990:T:A	K491N	0.998
12:6638990:T:G	K491N	0.998
12:6640110:A:G	W459R	0.998
12:6640110:A:T	W459R	0.998
12:6646508:C:G	C111S	0.998
12:6646509:A:T	C111S	0.998
12:6646512:G:T	R110S	0.998
12:6646523:A:G	F106S	0.998
12:6646531:G:C	F103L	0.998
12:6646531:G:T	F103L	0.998
12:6646533:A:G	F103L	0.998
12:6646568:C:G	C91S	0.998
12:6646569:A:T	C91S	0.998
12:6646571:A:T	V90D	0.998
12:6646817:T:A	E80V	0.998
12:6638324:C:A	W530C	0.997
12:6638324:C:G	W530C	0.997
12:6638979:C:G	C495S	0.997

dbSNP variants (sampled 300 via entrez): RS1000674503 (12:6639706 G>A,T), RS1000853958 (12:6638475 G>A,T), RS1000855335 (12:6646642 GGAC>G), RS1000945614 (12:6643163 G>A), RS1001125348 (12:6646377 G>A,C), RS1001531832 (12:6649421 C>A), RS1002287378 (12:6643999 G>A), RS1002290280 (12:6637599 C>G,T), RS1002854948 (12:6643469 A>C), RS1002982979 (12:6649302 G>A), RS1003075502 (12:6639931 A>G,T), RS1003240234 (12:6641884 CA>C,CAA), RS1003289096 (12:6645556 T>G), RS1003313500 (12:6648066 C>G), RS1003389025 (12:6638532 A>G)

Disease associations

OMIM: gene MIM:608352 | disease phenotypes: MIM:218340, MIM:615122, MIM:202370

GenCC curated gene-disease

Mondo (4): temtamy syndrome (MONDO:0009033), lymphoproliferative syndrome 2 (MONDO:0014054), peroxisome biogenesis disorder 2B (MONDO:0008736), brain neoplasm (MONDO:0021211)

Orphanet (3): Temtamy syndrome (Orphanet:1777), Combined immunodeficiency due to CD27 deficiency (Orphanet:238505), Neonatal adrenoleukodystrophy (Orphanet:44)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C536959	Temtamy syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	4
aristolochic acid I	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases methylation	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
erastin	increases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
theaflavin-3,3’-digallate	affects expression	1
Fulvestrant	increases methylation, affects cotreatment	1
Acetaminophen	increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Endosulfan	increases expression	1
Estradiol	decreases expression	1
Indomethacin	increases expression	1
Phthalic Acids	increases methylation	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Antirheumatic Agents	decreases expression	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00075166	PHASE4	COMPLETED	Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors
NCT00336531	PHASE4	COMPLETED	Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation
NCT00395863	PHASE4	COMPLETED	Multihance at 3 Tesla (3T) in Brain Tumors
NCT00415467	PHASE4	TERMINATED	Treatment of Resectable Malignant Brain Tumors
NCT00576472	PHASE4	COMPLETED	Learning Impairments Among Survivors of Childhood Cancer
NCT00952081	PHASE4	COMPLETED	A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients
NCT02057367	PHASE4	COMPLETED	Scalp Nerve Block and Opioid Consumption in Brain Surgery
NCT02334722	PHASE4	COMPLETED	1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
NCT02558569	PHASE4	COMPLETED	The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block
NCT02670161	PHASE4	ENROLLING_BY_INVITATION	Quality Improvement and Practice Based Research in Neurology Using the EMR
NCT02713087	PHASE4	COMPLETED	Vasopressor Effects in Anesthetized Patients
NCT02810899	PHASE4	COMPLETED	Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy
NCT02964416	PHASE4	COMPLETED	Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery
NCT04266665	PHASE4	COMPLETED	Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome
NCT04313374	PHASE4	COMPLETED	Integrated Pulmonary Index and Opioid Based Patient Controlled Analgesia
NCT05141877	PHASE4	UNKNOWN	Influences of Propofol and Sevoflurane Anesthesia in Brain Tumor
NCT05202899	PHASE4	UNKNOWN	Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniotomy
NCT05926336	PHASE4	RECRUITING	The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
NCT00002875	PHASE3	COMPLETED	Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma
NCT00002944	PHASE3	COMPLETED	Combination Chemotherapy in Treating Children With Progressive Brain Tumors
NCT00045968	PHASE3	UNKNOWN	Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
NCT00054795	PHASE3	COMPLETED	Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)
NCT00078988	PHASE3	COMPLETED	High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas
NCT00085098	PHASE3	COMPLETED	Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor
NCT00088166	PHASE3	COMPLETED	XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
NCT00124761	PHASE3	COMPLETED	A Trial Comparing Radiosurgery With Surgery for Solitary Brain Metastases
NCT00135876	PHASE3	COMPLETED	Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients
NCT00138788	PHASE3	COMPLETED	Brain Metastases Study: Radiotherapy Fractionation Schemes in the Treatment of Brain Metastases
NCT00181350	PHASE3	COMPLETED	Serial CT Scans in Fractionated Stereotactic Radiotherapy
NCT00226655	PHASE3	COMPLETED	An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies
NCT00226668	PHASE3	WITHDRAWN	XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
NCT00241670	PHASE3	COMPLETED	Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid
NCT00280475	PHASE3	COMPLETED	A Trial of Postoperative Whole Brain Radiation Therapy vs. Salvage Stereotactic Radiosurgery Therapy for Metastasis
NCT00369785	PHASE3	COMPLETED	Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
NCT00418691	PHASE3	TERMINATED	Effects of Methylphenidate Versus Sustained Release Methylphenidate on Cognitive Functioning
NCT00681551	PHASE3	COMPLETED	Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis
NCT00716976	PHASE3	COMPLETED	Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
NCT01601314	PHASE3	COMPLETED	Perioperative Magnesium Sulphate as a Cerebral Protector in Neurosurgical Patients
NCT01655927	PHASE3	UNKNOWN	Efficacy of Tranexamic Acid in Brain Tumor Resections
NCT02667587	PHASE3	COMPLETED	An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)